CoronaryAtlas logo
CoronaryAtlas
cfDNA
Pathway / Myocardial injury (shared endpoint)

cfDNA

other

Cell-free DNA released from necrotic myocardium, reflecting infarct size and severity in acute myocardial infarction.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleCell-free DNA released during cardiomyocyte necrosis; AMI severity marker.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
63
C — non-Type-I
72
A — assay feasibility
45
E — evidence strength
32
T1DI (composite)
7
Specificity differential (R−C)-9.2
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Method depends on analyte chemistry
Reagent / substrate
Analyte-specific
Platform
Variable
Turnaround · availability
Research · Research

Literature evidence(2)